Steve Pascolo

This inventor holds 24 USPTO granted patents and 23 published patent applications, plus 2 CIPO patents and 15 EPO patents, primarily in RNA Therapeutics. Top assignees: Curevac Ag, Biontech Ag, Biontech Se. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steve Pascolo. Retrieved from https://idiyas.com/inventor/steve-pascolo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 23)

% Patents Active = 58.3

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 21)

Average Co-Inventor Count = 1.9

ph-index = 14

Forward Citations = 656(Granted Patents)

Location History:

Tübingen, DE (2016 - 2019)
Zürich, CH (2020 - 2021)
Tubingen, DE (2012 - 2022)
Zurich, CH (2017 - 2023)

Company Filing History:

Curevac Real Estate Gmbh

Curevac Manufacturing Gmbh

patents

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Cytotoxic Particles

RNA Formulations

Immunomodulation

mRNA Stabilisation

Pharmaceutical Composition

Therapeutic Applications

Tumour Diseases

Alkaline Earth Metals

Single Stranded RNA

Double Stranded RNA

Endosome Destabilizing Agents

Immunostimulating Agents

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12263215 - Cytotoxic immunostimulating particles and uses thereof (2025-04-01),

2. 11661634 - Method for producing RNA (2023-05-30),

3. 11421038 - RNA-coded antibody (2022-08-23),

4. 11369691 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2022-06-28),

5. 11268157 - Method for producing RNA (2022-03-08),

6. 11135312 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2021-10-05),

7. 10980875 - Cytotoxic immunostimulating particles and uses thereof (2021-04-20),

8. 10729785 - Particles comprising protamine and RNA in combination with endosome destabilizing agents (2020-08-04),

9. 10711315 - Method for producing RNA (2020-07-14),

10. 10646576 - Immunostimulating-toxic RNA in alkaline earth metal formulation (2020-05-12),

11. 10626400 - Stabilised formulations of RNA (2020-04-21),

12. 10568972 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2020-02-25),

13. 10188748 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2019-01-29),

14. 10172960 - Particles comprising single stranded RNA and double stranded RNA for immunomodulation (2019-01-08),

15. 10017826 - Method for producing RNA (2018-07-10),

Title: Steve Pascolo: Innovator in RNA Technology

Introduction

Steve Pascolo is a notable inventor based in Zurich, Switzerland, recognized for his significant contributions to the field of RNA technology. With 23 patents to his name, Pascolo’s work primarily focuses on methods related to RNA production and its applications in healthcare.

Latest Patents

Among his latest patents is a groundbreaking invention related to a method for producing RNA. This method is designed to be scalable and aims to provide RNA at high purity levels while adhering to GMP and cGMP-compliant conditions. It includes specific processes for quality control in the manufacturing of template DNA and in the method for producing RNA, particularly through in vitro transcription. Another significant patent focuses on RNA-coded antibodies, describing the use of non-modified or modified RNA for the expression of such antibodies. This innovation has potential applications in developing pharmaceutical compositions, including passive vaccines for the treatment of various diseases such as tumors, cancer, cardiovascular issues, infectious diseases, autoimmune disorders, viral diseases, and even in gene therapy.

Career Highlights

Steve Pascolo has had a distinguished career, having worked with prominent companies such as CureVac AG and BioNTech AG. His expertise in RNA technology has positioned him as a leader in the industry, contributing to advancements that have the potential to revolutionize medical treatment.

Collaborations

Throughout his career, Pascolo has collaborated with several notable individuals, including Florian Von Der Mülbe and Ingmar Hoerr. These partnerships have fostered innovation and the development of new technologies that push the boundaries of current scientific understanding.

Conclusion

In conclusion, Steve Pascolo's contributions to RNA technology reflect his commitment to advancing medical science. His inventions and collaborations continue to pave the way for new treatments and therapies, underscoring the importance of innovation in the field of healthcare.

Profile summary based on public USPTO records.